Can I Take Creatine with Jardiance?

How Jardiance Works and Why the Kidneys Matter

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, preventing reabsorption of roughly 90 grams of glucose per day and sending it into the urine. That mechanism is inherently renal: the drug's glycosuric effect depends on adequate kidney function, and the drug itself has direct hemodynamic effects on the glomerulus that lower intraglomerular pressure.

Renal Dosing Thresholds You Need to Know

The FDA-approved prescribing information for Jardiance states that the drug is not recommended in patients with an eGFR <20 mL/min/1.73 m² for its glycemic indication, though the CKD indication allows use down to an eGFR of 20 mL/min/1.73 m² for cardiorenal protection [1]. The EMPA-KIDNEY trial (N=6,609) confirmed that empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% versus placebo in patients with CKD across a wide eGFR range, reinforcing just how tightly this drug's safety profile is tied to renal monitoring [2].

Because eGFR is calculated directly from serum creatinine (via the CKD-EPI 2021 or MDRD equation), anything that artificially raises serum creatinine can make the kidneys appear sicker than they are. That is the core of the creatine-Jardiance issue.

What Triggers Jardiance Dose Reduction or Discontinuation

Clinicians use two primary markers. First, eGFR falling below the indication-specific threshold (20 or 45 mL/min/1.73 m² depending on the indication). Second, a sustained rise in serum creatinine of greater than 0.3 mg/dL above baseline, which some guidelines treat as a signal for acute kidney injury review. If a patient on creatine supplements has serum creatinine reading 0.3 to 0.5 mg/dL higher than their true value, a clinician could incorrectly reduce or stop a drug that is actually protecting that patient's heart and kidneys.

What Creatine Supplementation Does to Creatinine Levels

Creatine is a naturally occurring compound synthesized in the liver and kidneys from arginine and glycine. Roughly 95% of the body's creatine is stored in skeletal muscle, where it buffers ATP availability during high-intensity exercise. Supplemental creatine monohydrate is one of the most studied sports-nutrition compounds in existence, with more than 500 peer-reviewed trials published over three decades [3].

The Creatinine Conversion Problem

When phosphocreatine is broken down in muscle, it is non-enzymatically converted to creatinine, which then exits into the bloodstream and is filtered by the kidney. More creatine in the body means more creatinine in the blood. A 2003 crossover trial published in the Journal of Renal Nutrition (N=18 healthy subjects) found that five days of creatine loading at 20 g/day raised serum creatinine by a mean of 0.28 mg/dL, an increase that persisted at a lower magnitude (0.08 to 0.12 mg/dL) during the 5 g/day maintenance phase [4]. A 2021 systematic review in Nutrients confirmed that short-term high-dose creatine consistently elevates serum creatinine by 10 to 30% without genuine renal impairment in healthy individuals [5].

The key distinction is between a rise in serum creatinine that reflects tubular damage versus one that simply reflects increased substrate load. Creatine does the latter.

Does Creatine Actually Damage the Kidneys?

Short answer: not in people with normal baseline kidney function. A 2019 randomized controlled trial (N=46) published in Medicine and Science in Sports and Exercise found no change in cystatin C-based eGFR (which is creatinine-independent) after 12 weeks of creatine supplementation at 5 g/day, despite a statistically significant rise in creatinine-based eGFR decline [6]. Cystatin C is a protein filtered at the glomerulus and is not affected by muscle creatine metabolism, making it the preferred marker when creatine use is suspected of confounding results.

In patients who already have CKD, the safety data are thinner. A Cochrane-style systematic review of creatine in renal patients found no controlled trials large enough to draw conclusions about genuine injury risk [7]. Clinicians should exercise added caution in that population.

Is There a Direct Pharmacokinetic Interaction?

No. Empagliflozin is primarily metabolized via UGT1A3 and UGT2B7 glucuronidation, with minor contributions from UGT1A8 and UGT1A9 [1]. Creatine is not a substrate, inducer, or inhibitor of any UGT enzyme, nor does it bind to plasma proteins in a way that would displace empagliflozin. Neither compound alters the other's peak plasma concentration (Cmax) or area under the curve (AUC).

There is also no meaningful pharmacodynamic clash. Creatine does not raise blood glucose, alter insulin secretion, change urinary glucose excretion, or affect blood pressure in ways that would oppose Jardiance's mechanisms. A 12-week double-blind RCT in type 2 diabetes patients (N=25) published in Diabetes Care found that creatine supplementation at 5 g/day actually improved glycemic control, lowering HbA1c by a mean of 1.1% more than placebo, likely by increasing GLUT4 translocation in skeletal muscle [8].

Why "No Pharmacokinetic Interaction" Still Leaves a Real Problem

The absence of a PK interaction does not make this combination automatically trouble-free. The lab-interpretive problem described above is clinically real. Consider a patient with CKD stage G3a (eGFR 52 mL/min/1.73 m²) who starts creatine supplementation. A 15% creatinine elevation pushes their apparent eGFR to roughly 44 mL/min/1.73 m², crossing the threshold below which some prescribers scale back empagliflozin. If the prescriber does not know the patient is taking creatine, they may reduce a drug that is actively protecting that patient's kidneys.

SGLT2 Inhibitors, Creatine, and the Muscle-Building Patient

Patients taking Jardiance for heart failure or CKD are often older adults or people managing metabolic syndrome. A growing subset of these patients also pursue resistance training, and creatine is one of the few supplements with consistent evidence for improving lean mass and strength in older adults. A meta-analysis of 22 RCTs in adults over 55 published in the British Journal of Sports Medicine (N=721) found that creatine supplementation combined with resistance training increased lean body mass by a mean of 1.37 kg more than resistance training plus placebo over 12 to 52 weeks [9].

This creates a genuine clinical scenario where both Jardiance and creatine may be medically or lifestyle-appropriate for the same person.

Creatine and Volume Status: A Minor Consideration

Creatine pulls water into muscle cells via osmosis during the loading phase. The first week of a 20 g/day loading protocol typically adds 0.5 to 1.5 kg of intracellular water weight. Jardiance, on the other hand, produces osmotic diuresis through glycosuria and causes a mild reduction in plasma volume (roughly 200 to 400 mL in clinical trials). These effects are in opposite directions and do not meaningfully interact, but patients with heart failure who are already on tight fluid-management protocols should mention creatine loading to their cardiologist before starting, given the transient water retention.

Creatine Dosing Strategy When Taking Jardiance

The standard loading phase (20 g/day divided into four 5 g doses for 5 to 7 days) is the period of highest creatinine elevation. Skipping the loading phase and going straight to 3 to 5 g/day produces the same muscle saturation over approximately 28 days with a smaller and more gradual creatinine rise, which is easier for a clinician to track and interpret. For patients on Jardiance whose eGFR is already in the 30 to 60 mL/min/1.73 m² range, starting with this "no-load" approach and checking serum creatinine, cystatin C, and eGFR at four weeks is a sensible protocol.

Monitoring Protocol: What Labs to Check and When

Kidney function monitoring is standard practice for all patients on empagliflozin. The American Diabetes Association's 2024 Standards of Care recommend checking eGFR and urine albumin-to-creatinine ratio (UACR) at baseline and at least annually in all patients with diabetes and CKD, with more frequent monitoring when eGFR is below 60 mL/min/1.73 m² [10]. Adding creatine supplementation on top of this does not eliminate the need for monitoring. It makes interpreting the results more demanding.

Recommended Lab Panel Before Starting Creatine

Before adding creatine, your prescriber should document a baseline that includes serum creatinine, cystatin C (to allow creatinine-independent eGFR estimation), blood urea nitrogen (BUN), UACR, and serum potassium. This gives a reference point that creatine cannot retroactively confound.

What to Recheck and When

Recheck serum creatinine, cystatin C, and UACR at four weeks after starting creatine maintenance dosing. If creatinine-based eGFR has fallen but cystatin C-based eGFR is stable, the drop is almost certainly a creatine artifact and empagliflozin does not need to be adjusted. If both markers have deteriorated, a genuine renal event is possible and warrants prompt clinical evaluation.

The following table summarizes the monitoring framework.

| Timepoint | Labs | Interpretation Note | |---|---|---| | Baseline (before creatine) | Cr, Cys-C, BUN, UACR, K+ | Establishes creatinine-independent reference | | 4 weeks after starting creatine | Cr, Cys-C, eGFR (both equations) | Compare Cr-eGFR vs. Cys-C-eGFR drift | | 12 weeks | Cr, Cys-C, UACR | Confirm stable or improving trajectory | | Annually (ongoing) | Full panel per ADA 2024 guidelines | Standard Jardiance monitoring |

The Role of Cystatin C in This Specific Combination

Cystatin C deserves special mention here. Unlike creatinine, cystatin C is produced at a constant rate by all nucleated cells, is freely filtered at the glomerulus, and is completely reabsorbed and catabolized in the tubules. Its serum level reflects glomerular filtration rate without any contribution from creatine metabolism. The 2021 CKD-EPI equation using cystatin C alone carries a lower bias than the creatinine-based equation in patients with abnormal muscle mass or high dietary creatine intake, per the National Kidney Foundation's 2021 Task Force Report [11]. Ordering cystatin C alongside creatinine costs approximately $25, $60 out-of-pocket and can prevent a clinically significant misclassification.

Practical Guidance: How to Take Creatine Safely with Jardiance

The following steps consolidate the clinical reasoning above into a workable action plan.

Before You Start Creatine

Tell your prescribing physician and pharmacist that you plan to take creatine. This is not optional. A prescriber who does not know about creatine use cannot correctly interpret a lab result that shows a rising creatinine. Ask for a baseline cystatin C in addition to the standard creatinine panel.

Confirm your current eGFR category. If you are in CKD stage G3b (eGFR 30 to 44 mL/min/1.73 m²) or lower, the decision to add creatine should involve your nephrologist, not just your primary care provider.

Choosing Your Creatine Product

Use creatine monohydrate. It is the only form tested in long-term clinical trials, the least expensive, and the only form for which the creatinine-elevation effect has been characterized. Proprietary blends labeled as "Kre-Alkalyn," "creatine HCl," or "buffered creatine" have no superior efficacy data and introduce unnecessary uncertainty about dosing.

Third-party-tested products bearing NSF Certified for Sport or Informed Sport certification are preferable, especially in patients managing blood glucose, because contaminated supplements occasionally contain undisclosed ingredients that can affect metabolic markers.

Skip the Loading Phase

As noted above, starting at 3 to 5 g/day without loading keeps the creatinine rise smaller and more gradual, making lab interpretation easier. You will reach muscle saturation in approximately four weeks rather than one week. For most non-competitive athletes, the difference in timeline is not clinically meaningful.

Hydration

Both Jardiance and creatine affect fluid dynamics, Jardiance through osmotic diuresis and creatine through intramuscular water retention. Patients should target a urine color of pale yellow and drink at least 2 liters of water daily. Patients with heart failure managing fluid restriction should review this target with their care team before adjusting intake.

Special Populations: CKD, Heart Failure, and Older Adults

Patients with CKD Stages G3, G4

The EMPA-KIDNEY trial enrolled patients with eGFR as low as 20 mL/min/1.73 m², and the absolute risk reduction in kidney disease progression was largest in that subgroup. These patients are also the most vulnerable to creatine-driven lab confounding. Adding creatine in CKD G3b or G4 requires cystatin C monitoring at every visit and a shared decision-making discussion about whether the performance benefits justify the interpretive complexity.

The 2022 KDIGO CKD guideline does not specifically address creatine supplementation but does state that "accurate assessment of GFR is especially important when approaching treatment thresholds for SGLT2 inhibitors" [12]. That principle applies directly here.

Patients with Heart Failure

The EMPEROR-Reduced (N=3,730) and EMPEROR-Preserved (N=5,988) trials established empagliflozin's mortality and hospitalization benefit in both HFrEF and HFpEF, and heart failure patients are increasingly encouraged to engage in supervised resistance exercise programs [13, 14]. Creatine is sometimes considered in cardiac rehabilitation settings to augment exercise tolerance. There is no specific contraindication, but the fluid retention of the loading phase (0.5 to 1.5 kg over one week) must be weighed against a patient's dry-weight target.

Older Adults Over 65

Older adults tend to have lower muscle mass, which means their serum creatinine is often already lower than expected for their true GFR. Paradoxically, this can make the creatinine elevation from creatine supplementation proportionally more distorting. A 70-year-old with a baseline creatinine of 0.7 mg/dL who sees a 0.2 mg/dL rise from creatine will show a calculated eGFR drop that looks alarming even though the absolute change is modest.

What Clinicians and Guidelines Say

The American Diabetes Association's 2024 position on SGLT2 inhibitors states: "Empagliflozin, canagliflozin, and dapagliflozin reduce eGFR slightly in the first weeks of use due to hemodynamic effects; this early dip is expected, reversible, and should not prompt discontinuation unless eGFR falls below the threshold for the relevant indication" [10].

Dr. Katherine Tuttle, a nephrologist at the University of Washington and co-author of the KDIGO 2022 CKD guidelines, has written that "confounders of serum creatinine measurement, including dietary protein intake and creatine supplements, must be identified and accounted for before making SGLT2 inhibitor dosing decisions based on eGFR alone" [12].

These perspectives confirm that the clinical community has already recognized this interpretive challenge. The solution is not to avoid creatine categorically but to measure more carefully.

Summary of the Interaction Classification

To be precise about terminology: this combination carries a pharmacokinetic interaction risk of zero and a pharmacodynamic interaction risk of negligible to low, with the primary hazard being lab-interpretive, not biological. In the Natural Medicines database interaction taxonomy, this would map to a "minor" interaction driven by laboratory confounding rather than adverse drug effect. The FDA drug label for Jardiance does not list creatine or creatinine-elevating supplements as a contraindication or warning [1].

The practical implication: patients should not stop creatine out of fear, and prescribers should not stop Jardiance because of a creatinine value obtained while a patient is supplementing. Order cystatin C. Compare the two eGFR values. Make decisions based on the full picture.

What to Tell Your Doctor at Your Next Appointment

Bring a list of every supplement you take to every appointment, including dose and brand. Specifically tell your prescriber: "I take creatine monohydrate at [dose] g per day. I would like a cystatin C level added to my next kidney panel so my eGFR can be assessed without the creatinine confound."

If your prescriber is unfamiliar with cystatin C-based eGFR, the NKF-ASN 2021 Task Force Report is freely available at ncbi.nlm.nih.gov and summarizes the clinical indications for the combined creatinine-cystatin C CKD-EPI equation [11].